Katja Kiseljak-Vassiliades

Katja Kiseljak-Vassiliades

Auto-generated profile, based on publicly available information

Katja Kiseljak-Vassiliades

Divisions of Endocrinology, Metabolism and Diabetes, University of Colorado , Aurora, CO 80045

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2006 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SHShuiying Hu
Shuiying Hu
DLDingxie Liu
Dingxie Liu
RTRalph P. Tufano
Ralph P. Tufano
KCKathryn A. Carson
Kathryn A. Carson
EREli Rosenbaum
Eli Rosenbaum
MXMingzhao Xing
Mingzhao Xing
The role of aberrant tumor suppressor gene methylation in the aggressiveness of papillary thyroid cancer (PTC) has not been documented. By showing promoter methylation‐induced gene silencing in PTC‐derived cell lines, we first demonstrated the functional consequence of methylation of several recently identified tumor suppressor genes, including those for tissue inhibitor of metalloproteinase‐3 (TIMP3), SLC5A8, death‐associated protein kinase (DAPK) and retinoic acid receptor β2 (RARβ2). We then investigated the role of methylation of these genes in the aggressiveness of PTC by examining the relationship of their aberrant methylation to clinicopathological characteristics and BRAF mutation in 231 primary PTC tumors. Methylation of TIMP3, SLC5A8 and DAPK was significantly associated with several aggressive features of PTC, including extrathyroidal invasion, lymph node metastasis, multifocality and advanced tumor stages. Methylation of these genes was also significantly associated with BRAF mutation in PTC, either individually or collectively in various combinations. Methylation of these genes, either individually or collectively, occurred more frequently in more aggressive classical and tall‐cell PTC subtypes than in less aggressive follicular‐variant PTC, with the latter known to infrequently harbor BRAF mutation. Several other tumor suppressor genes investigated were not methylated. These results suggest that aberrant methylation and hence silencing of TIMP3, SLC5A8, DAPK and RARβ2, in association with BRAF mutation, may be an important step in PTC tumorigenesis and progression.

1 January 2011 in Frontiers in Neuroendocrinology
Verified
Journal Article
Closed access
MWMargaret E. Wierman
Margaret E. Wierman
KKKatja Kiseljak-Vassiliades
Katja Kiseljak-Vassiliades
Stuart TobetStuart Tobet
Stuart Tobet

17 August 2014 in Endocrine
Verified
Journal Article
Closed access
PDF file
KKKatja Kiseljak-Vassiliades
Katja Kiseljak-Vassiliades
NCNichole E. Carlson
Nichole E. Carlson
MBManuel T. Borges
Manuel T. Borges
BKB. K. Kleinschmidt-DeMasters
B. K. Kleinschmidt-DeMasters
KLKevin O. Lillehei
Kevin O. Lillehei
MWMargaret E. Wierman
Margaret E. Wierman

2 August 2011 in Endocrinology
Verified
Journal Article
Open access
PDF file
KMKatherine A. Michaelis
Katherine A. Michaelis
AKAaron J. Knox
Aaron J. Knox
MXMei Xu
Mei Xu
KKKatja Kiseljak-Vassiliades
Katja Kiseljak-Vassiliades
MEMichael G. Edwards
Michael G. Edwards
MWMargaret E. Wierman
Margaret E. Wierman
Gonadotrope and null cell pituitary tumors cause significant morbidity, often presenting with signs of hypogonadism together with visual disturbances due to mass effects. Surgery and radiation are the only therapeutic options to date. To identify dysregulated genes and pathways that may play a role in tumorigenesis and/or progression, molecular profiling was performed on 14 gonadotrope tumors, with nine normal human pituitaries obtained at autopsy serving as controls. Bioinformatic analysis identified putative downstream effectors of tumor protein 53 (p53) that were consistently repressed in gonadotrope pituitary tumors, including RPRM, P21, and PMAIP1, with concomitant inhibition of the upstream p53 regulator, PLAGL1(Zac1). Further analysis of the growth arrest and DNA damage-inducible (GADD45) family revealed no change in the p53 target, GADD45α, but identified repression of GADD45β in pituitary tumors in addition to the previously reported inhibition of GADD45γ. Overexpression of GADD45β in LβT2 mouse gonadotrope cells blocked tumor cell proliferation and increased rates of apoptosis in response to growth factor withdrawal. Stable gonadotrope cell transfectants expressing increased GADD45β showed decreased colony formation in soft agar, confirming its normal role as a tumor suppressor. Unlike previous studies of GADD45γ in pituitary tumors and α and β in other tumors, bisulfite sequencing showed no evidence of hypermethylation of the GADD45β promoter in human pituitary tumor samples to explain the repression of its expression. Thus, GADD45β is a novel pituitary tumor suppressor whose reexpression blocks proliferation, survival, and tumorigenesis. Together these studies identify new targets and mechanisms to explore in pituitary tumor initiation and progression.

4 April 2012 in Cancer
Verified
Journal Article
Open access
PDF file
AWAndrew J. Weickhardt
Andrew J. Weickhardt
MRMicol S. Rothman
Micol S. Rothman
SSSmita Salian‐Mehta
Smita Salian‐Mehta
KKKatja Kiseljak‐Vassiliades
Katja Kiseljak‐Vassiliades
AOAna B. Oton
Ana B. Oton
DCD. Ross Camidge
D. Ross Camidge
BACKGROUND: The objective of this study was to document the differences in testosterone (T) levels between crizotinib‐treated and noncrizotinib‐treated patients with metastatic nonsmall cell lung cancer (NSCLC).METHODS: Testosterone levels were measured in 19 men with metastatic NSCLC who received crizotinib and in 19 men with metastatic NSCLC who did not receive crizotinib. Clinical characteristics of the patients were compared, and additional hormone assays were performed as appropriate. Two patients who began crizotinib and 4 patients who had dose interruptions or who stopped crizotinib therapy had serial hormone measurements, permitting the documentation of dynamic hormone changes on and off crizotinib treatment.RESULTS: Total T levels were low (<241 ng/dL) in 19 of 19 (100%) crizotinib‐treated men and in 6 of 19 men (32%) with metastatic NSCLC who did not receive crizotinib (mean T levels, 131 ng/dL and 311 ng/dL, respectively; P = .0002). Only 1 in 5 patients who had anaplastic lymphoma kinase (ALK) gene rearrangements and had not yet received crizotinib had low T. The initiation of crizotinib in 2 patients who had previously normal T levels was associated with a rapid decreases in T and in luteinizing hormone and follicle stimulating hormone levels within 14 to 21 days. Discontinuation of crizotinib led to increases back to normal T levels.CONCLUSIONS: Crizotinib therapy caused rapid suppression of T levels in men. The current results indicated that the site of action must include a central (hypothalamic or pituitary) effect, but additional direct testicular effects could not be excluded. Further work is required to assess the correlation between low T levels and crizotinib side effects as well as the exact molecular mechanism and site of drug toxicity. Cancer 2012. © 2012 American Cancer Society.

1 June 2016 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
SNSean A. Newsom
Sean A. Newsom
JBJoseph T. Brozinick
Joseph T. Brozinick
KKKatja Kiseljak-Vassiliades
Katja Kiseljak-Vassiliades
ASAllison N. Strauss
Allison N. Strauss
SBSamantha D. Bacon
Samantha D. Bacon
BBBryan C. Bergman
Bryan C. Bergman
Several recent reports indicate that the balance of skeletal muscle phosphatidylcholine (PC) and phosphatidylethanolamine (PE) is a key determinant of muscle contractile function and metabolism. The purpose of this study was to determine relationships between skeletal muscle PC, PE and insulin sensitivity, and whether PC and PE are dynamically regulated in response to acute exercise in humans. Insulin sensitivity was measured via intravenous glucose tolerance in sedentary obese adults (OB; n = 14), individuals with type 2 diabetes (T2D; n = 15), and endurance-trained athletes (ATH; n = 15). Vastus lateralis muscle biopsies were obtained at rest, immediately after 90 min of cycle ergometry at 50% maximal oxygen consumption (V̇o2 max), and 2-h postexercise (recovery). Skeletal muscle PC and PE were measured via infusion-based mass spectrometry/mass spectrometry analysis. ATH had greater levels of muscle PC and PE compared with OB and T2D ( P < 0.05), with total PC and PE positively relating to insulin sensitivity (both P < 0.05). Skeletal muscle PC:PE ratio was elevated in T2D compared with OB and ATH ( P < 0.05), tended to be elevated in OB vs. ATH ( P = 0.07), and was inversely related to insulin sensitivity among the entire cohort ( r = −0.43, P = 0.01). Muscle PC and PE were altered by exercise, particularly after 2 h of recovery, in a highly group-specific manner. However, muscle PC:PE ratio remained unchanged in all groups. In summary, total muscle PC and PE are positively related to insulin sensitivity while PC:PE ratio is inversely related to insulin sensitivity in humans. A single session of exercise significantly alters skeletal muscle PC and PE levels, but not PC:PE ratio.